Medacta Announces First U.S. Surgery with MectaScrew PEEK following FDA Clearance
- 46
Media Release CASTEL SAN PIETRO, 4 November 2019 - Medacta is proud to announce the successful completion of the first U.S. surgery utilizing its MectaScrew PEEK Interference Screw for ligament refixation. The MectaScrew PEEK, which received clearance from the U.S. Food and Drug Administration (FDA) in June, is one of Medacta's most recent sports medicine offerings. As part of the Medacta Single Bundle ACL set, it is intended for knee arthroscopy and indicated for reconstructive treatment of ruptured anterior and posterior cruciate ligaments for hamstring and bone-tendon-bone repairs. The MectaScrew PEEK features several noteworthy design features, including a blunt thread, which protects the graft from laceration, while ensuring fixation strength, as well as sharp threads at the driver tip that gradually increase in width as the screw goes from distal to proximal to facilitate screw insertion. The associated driver also features a tip design that enables strong retention of the screw once positioned on the tip of the instrument. The first single bundle ACL surgery in the United States was completed by Akbar Nawab, M.D., at Ellis and Badenhausen Orthopaedics (Louisville, Kentucky) on September 24. "The implant and associated instrumentation performed very well," said Dr. Nawab. "The screw started nicely and provided secure fixation without any damage to the graft, while the instrumentation's ergonomic design made each instrument easy and natural to use. I feel very confident starting my patient in an accelerated rehabilitation program." This surgery follows the first single bundle ACL performed in Australia in August 2019 and is the start of Medacta's sports medicine presence in the United States. Contact About Medacta Issuer: Medacta Group SA Key word(s): Advertisement/Communication
End of Corporate News |
Language: | English |
Company: | Medacta Group SA |
Strada Regina | |
6874 Castel San Pietro | |
Switzerland | |
Phone: | +41 91 696 6060 |
E-mail: | [email protected], [email protected] |
Internet: | www.medacta.com |
ISIN: | CH0468525222 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 903815 |
End of News | EQS Group Media |
|
903815 04.11.2019
EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.